Morgan Stanley
IMDX

Morgan Stanley’s Insight Molecular Diagnostics IMDX Stock Holding History

Morgan Stanley’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$118K Buy
36,088
+175
+0.5% +$1.02K ﹤0.01% 6088
2025
Q4 		$269K Sell
35,913
-26,295
-42% -$148K ﹤0.01% 5805
2025
Q3 		$207K Hold
62,208
– – ﹤0.01% 5875
2025
Q2 		$188K Buy
62,208
+500
+0.8% +$1.51K ﹤0.01% 5876
2025
Q1 		$189K Hold
61,708
– – ﹤0.01% 5750
2024
Q4 		$147K Sell
61,708
-10,581
-15% -$28.8K ﹤0.01% 5899
2024
Q3 		$206K Sell
72,289
-6,407
-8% -$19.9K ﹤0.01% 5744
2024
Q2 		$232K Sell
78,696
-44,515
-36% -$122K ﹤0.01% 5599
2024
Q1 		$361K Sell
123,211
-122,735
-50% -$379K ﹤0.01% 5464
2023
Q4 		$615K Buy
245,946
+106,408
+76% +$327K ﹤0.01% 5538
2023
Q3 		$435K Sell
139,538
-9
-0% -$33 ﹤0.01% 5227
2023
Q2 		$642K Buy
139,547
+137,720
+7,538% +$694K ﹤0.01% 5096
2023
Q1 		$12.9K Sell
1,827
-375
-17% -$2.78K ﹤0.01% 6792
2022
Q4 		$14.1K Sell
2,202
-3,265
-60% -$36K ﹤0.01% 6813
2022
Q3 		$80K Sell
5,467
-1,955
-26% -$33.8K ﹤0.01% 6189
2022
Q2 		$134K Sell
7,422
-2,386
-24% -$54.3K ﹤0.01% 6115
2022
Q1 		$292K Sell
9,808
-2,500
-20% -$79.9K ﹤0.01% 5708
2021
Q4 		$534K Buy
12,308
+8,096
+192% +$466K ﹤0.01% 5504
2021
Q3 		$300K Buy
4,212
+263
+7% +$24.2K ﹤0.01% 5786
2021
Q2 		$453K Buy
3,949
+132
+3% +$12.9K ﹤0.01% 5587
2021
Q1 		$396K Sell
3,817
-488
-11% -$46.3K ﹤0.01% 5286
2020
Q4 		$205K Buy
4,305
+2,291
+114% +$84.1K ﹤0.01% 5576
2020
Q3 		$56K Sell
2,014
-493
-20% -$14.1K ﹤0.01% 5685
2020
Q2 		$96K Buy
2,507
+719
+40% +$37.1K ﹤0.01% 5419
2020
Q1 		$87K Sell
1,788
-1,461
-45% -$71.6K ﹤0.01% 5241
2019
Q4 		$146K Buy
3,249
+1,148
+55% +$41.4K ﹤0.01% 5524
2019
Q3 		$88K Buy
2,101
+482
+30% +$18.9K ﹤0.01% 5484
2019
Q2 		$81K Sell
1,619
-490
-23% -$40.7K ﹤0.01% 5417
2019
Q1 		$167K Buy
2,109
+637
+43% +$41.1K ﹤0.01% 5159
2018
Q4 		$41K Buy
1,472
+11
+0.8% +$396 ﹤0.01% 5807
2018
Q3 		$73K Buy
1,461
+927
+174% +$47.8K ﹤0.01% 5781
2018
Q2 		$28K Sell
534
-270
-34% -$13.3K ﹤0.01% 6065
2018
Q1 		$34K Buy
804
+2
+0.2% +$132 ﹤0.01% 5988
2017
Q4 		$75K Buy
802
+309
+63% +$34.8K ﹤0.01% 5726
2017
Q3 		$75K Buy
493
+185
+60% +$19.4K ﹤0.01% 5654
2017
Q2 		$32K Buy
308
+147
+91% +$16.7K ﹤0.01% 5971
2017
Q1 		$19K Buy
161
+104
+182% +$12K ﹤0.01% 6107
2016
Q4 		$8K Buy
57
+55
+2,750% +$6.06K ﹤0.01% 6202
2016
Q3 		$0 Sell
2
-47
-96% -$3.79K ﹤0.01% 6542
2016
Q2 		$3K Buy
49
+24
+96% +$2.24K ﹤0.01% 6305
2016
Q1 		$2K Buy
+25
New +$2.21K ﹤0.01% 6403

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Morgan Stanley's IMDX Position: Q1 2026 in Review

Morgan Stanley increased its Insight Molecular Diagnostics (IMDX) stake by 0.49% in Q1 2026, buying an estimated $1.02K and bringing the position to 36,088 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #6088.

Morgan Stanley first reported a position in IMDX in Q1 2016 and has held it in 41 quarters since. The position peaked at $642K in Q2 2023. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • Morgan Stanley held 36,088 shares of Insight Molecular Diagnostics worth $118K as of Q1 2026.
  • Morgan Stanley bought 175 Insight Molecular Diagnostics shares in Q1 2026, an estimated $1.02K.
  • Insight Molecular Diagnostics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6088 holding.
  • Morgan Stanley first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 41 quarters since.
  • Morgan Stanley's Insight Molecular Diagnostics position peaked at $642K in Q2 2023.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.